Knowledge Library
Quantitative Histopathology of Fibrosis in an Animal Model of NASH
The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could induced by nutritional (high-fat died with high cholesterol, methionine and choline deficient diet, etc), chemical (carbon tetrachloride, thioacetamide, α-naphthylisothiocyanate etc.), and surgical (bile duct ligation) means, the clinical relevance of the resulting fibrosis remains an …Read More >
Protein Degradation: Shifting the Paradigm of Resistance and Undruggables for Unmet Medical Needs in Cancer, Neuroscience, and Beyond
INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) With a recent $120 million IPO, a $55 million Series C, and a Pfizer R&D deal potentially worth $830 million, Arvinas is poised to transform the “undruggable” landscape, giving patients and healthcare providers new hope. Arvinas is doing this by developing a new …Read More >
Empowering Organic Syntheses with Quantum Mechanics Analyses
Syntheses of specifically functionalized molecules continue to be rate limiting steps (RLS) in drug discovery. Improvement in this RLS means investing only in reactions/synthetic sequences that are more likely to succeed. Structural diversifications, different substitution patterns or unique heterocyclic systems can often adversely impact the crucial step(s) of established synthetic sequences or development of feasible …Read More >
The Synthesis of an Entrepreneur: Merging a Passion for Biochemistry, Synthetic Chemistry, and Bioactive Molecules in Academia
INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) Synthetic chemist Joseph Ready believes a huge amount of innovation in the drug industry comes from academia. Academic science is arguably the greatest source of innovation in our ecosystem, yet faces challenges when considering the transition from the lab to early stage …Read More >
Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond
INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) As a self-proclaimed drug hunter, Phil Jones is on a mission to identify the next generation of cancer medicines that improve the lives of patients with cancer. He leads a multi-disciplinary team of scientists at The University of Texas MD Anderson Cancer Center’s Institute …Read More >
Faster with high-speed fragment screening — Accelerate your drug discovery campaign
In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited the exploration of this undevelopable area. Today, the combination of novel chemical modalities and advanced technical approaches has resulted in new clinical candidates from previously undruggable targets. To accelerate your drug discovery campaign, WuXi AppTec´s …Read More >
Unlocking the potential of DEL | Inspire Hit Discovery
March 4, 2020 – By going commercial, DNA Encoded Library (DEL) technology facilitates rapid discovery and provides access to more chemical entities at lower cost. Over the years, DEL has become a disruptive drug discovery technology in comparison to traditional high-throughput screening (HTS) where it allows expedition of early stage drug discovery. However, DEL platforms don’t succeed …Read More >